 Crinetics Pharmaceuticals NASDAQ:CRNX was upgraded by analysts at BidaskClub from a sell rating to a hold rating in a report issued on Saturday, BidAskClub reports. Several other analysts have also commented on the stock. Zacks Investment Research lowered shares of Crinetics Pharmaceuticals from a buy rating to a hold rating in a research report on ... 